SRSF2 and myelodysplastic syndrome: Concurrent spliceosome gene mutations, such as SRSF2 and SF3B1, are associated with HR-MDS, higher bone marrow blast percentage, and deregulation of RNA splicing and DNA methylation pathways (66).